2009. Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen . Clinics. 64, 5 (May 2009), 415–420. DOI:https://doi.org/10.1590/S1807-59322009000500008.